263 filings
8-K
EPIX
Essa Pharma Inc
14 May 24
Results of Operations and Financial Condition
7:01am
10-Q
2024 Q2
EPIX
Essa Pharma Inc
Quarterly report
14 May 24
7:00am
S-8
EPIX
Essa Pharma Inc
5 Apr 24
Registration of securities for employees
4:57pm
8-K
EPIX
Essa Pharma Inc
7 Mar 24
Submission of Matters to a Vote of Security Holders
5:18pm
10-Q
2024 Q1
EPIX
Essa Pharma Inc
Quarterly report
13 Feb 24
7:01am
8-K
bweaf0
13 Feb 24
Results of Operations and Financial Condition
7:01am
8-K
ld1yfz
29 Jan 24
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
9:15am
DEFA14A
fixcf6zsi17ubd
26 Jan 24
Additional proxy soliciting materials
4:40pm
8-K
rqtwrm9shy6h
12 Dec 23
Results of Operations and Financial Condition
7:01am
8-K
oqfm92e3sqr6mep
6 Nov 23
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
4:57pm
424B5
du8zpplx97sqpz
3 Nov 23
Prospectus supplement for primary offering
9:44pm
8-K
fvrv6 5r0dd69tg5b
26 Oct 23
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
8:07pm
8-K
5pzn0h35b wrcd0sx3
23 Oct 23
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress
4:19pm
EFFECT
pg13ta
11 Oct 23
Notice of effectiveness
12:15am
CORRESP
pvnbh4ecekl3d n8
6 Oct 23
Correspondence with SEC
12:00am
CORRESP
p4fei5
6 Oct 23
Correspondence with SEC
12:00am
CORRESP
4ixni
3 Oct 23
Correspondence with SEC
12:00am